http://www.brightlands.com/companies-institutes/dsm-innovative-synthesis/
www.innosyn.comwww.innosyn.com

Royal DSM is a global science-based company active in health, nutrition and materials. By connecting its unique competences in Life Sciences and Materials Sciences DSM is driving economic prosperity, environmental progress and social advances to create sustainable value for all stakeholders simultaneously. DSM delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials. DSM’s 24,500 employees deliver annual net sales of around €10 billion. The company is listed on NYSE Euronext.

The focus of DSM Chemical Technology R&D B.V. (department Innovative Synthesis) lies on the development of sustainable and economic processes towards a broad range of these life science and material science products. Biocatalysis is an indispensable technology to achieve these routes and processes. Current focus of the mid and long term strategic research is on Oxidoreductases and Lyases including Monooxygenases and carbon-carbon lyases.

A main task of DSM in ROBOX will be to provide the overall coordination and project leader. DSM Innovative Synthesis is interested to develop scalable technology and processes for products for all markets of DSM and will therefore work on all four enzyme classes of the ROBOX project. DSM will also focus on development of biooxidation specific reaction engineering for robust for application of robust biocatalysts at large scale.

As a European industrial multinational with intimate knowledge of current and future markets DSM can to focus the expert activities along a limited number of process examples towards real-world products and thus demonstrate the maturity of all the required steps in the path from a market-relevant chemical idea to realization of the biocatalytic process. It is also crucial to identify the suitable opportunities in the market sector outside the pharmaceutical industry that represent the best opportunities for enzymatic processes in general and redox enzyme processes in particular.

key personnel: This email address is being protected from spambots. You need JavaScript enabled to view it., ROBOX Project Coordinator

“The research for this work has received funding from the European Union (EU) project ROBOX (grant agreement n° 635734) under EU’s Horizon 2020 Programme  Research and Innovation actions H2020-LEIT BIO-2014-1”